Research Study

A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Principal Investigator 
Robert Carruthers

Overview

ClinicalTrials.gov# 
NCT02200770
Status 
Recruiting
Study Start/End 
Aug 12, 2015 to Jun 23, 2018
Locations 
UBC Hospital
Name/Title 
Tara Martin, Research Coordinator
Phone 
604-822-1758
Email Address 
t.martin@ubc.ca
Purpose of Study 

To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.